Genelux Corp GNLX
Genelux Corp (Nasdaq: GNLX) is an oncology drug developer. Its lead program, Olvi-Vec (olvimulogene nanivacirepvec), is in Phase 3 for platinum-resistant/refractory ovarian cancer (OnPrime/GOG-3076).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Olvi-Vec | platinum-resistant/refractory ovarian cancer (Phase 3 OnPrime/GOG-3076, ongoing) | gene therapy | Phase 3 |
| Olvi-Vec | recurrent non-small cell lung cancer (Phase 2 VIRO-25, ongoing) | gene therapy | Phase 2 |
| Olvi-Vec | recurrent small cell lung cancer (Phase 1b/2 in China, co-sponsored with Newsoara) | gene therapy | Phase 1 |
Recent results and decisions
- Jan 5, 2026positive Interim data in 9 evaluable SCLC patients showed ORR 33% (3 PRs) and DCR 67%, with 2 of 3 PRs in the highest dose cohort (55% and 85% tumor shrinkage); generally well tolerated.
Overall response rate (ORR) of 33% (3/9 patients), including three PRs
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.